A detailed history of Gamma Investing LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Gamma Investing LLC holds 539 shares of ALNY stock, worth $125,667. This represents 0.01% of its overall portfolio holdings.

Number of Shares
539
Previous 554 2.71%
Holding current value
$125,667
Previous $152 Million 16.76%
% of portfolio
0.01%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 02, 2025

SELL
$232.27 - $300.43 $3,484 - $4,506
-15 Reduced 2.71%
539 $127 Million
Q3 2024

Oct 04, 2024

BUY
$233.81 - $287.01 $32,265 - $39,607
138 Added 33.17%
554 $152 Million
Q2 2024

Jul 02, 2024

BUY
$143.31 - $247.0 $29,378 - $50,635
205 Added 97.16%
416 $101 Million
Q1 2024

Apr 05, 2024

SELL
$146.51 - $198.2 $8,644 - $11,693
-59 Reduced 21.85%
211 $31.5 Million
Q4 2023

Feb 01, 2024

BUY
$151.41 - $196.57 $40,880 - $53,073
270 New
270 $46.7 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $28.7B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Gamma Investing LLC Portfolio

Follow Gamma Investing LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamma Investing LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gamma Investing LLC with notifications on news.